MAZE · XBRL financial data
Maze Therapeutics financial statements, every fiscal year
The same tables from 1 filing, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (MAZE's year ends in late December)
| In thousands of dollars | Dec 31, 2025 |
|---|---|
| Research and development | 108,448 |
| General and administrative | 34,451 |
| Total operating expenses | 142,899 |
| Operating income (loss) | (142,899) |
| Income tax expense (benefit) | 0 |
| Net income (loss) | (131,120) |
| Earnings per share, basic USD per share | (3.05) |
| Earnings per share, diluted USD per share | (3.05) |
| Weighted average shares, basic thousands of shares | 42,976 |
| Weighted average shares, diluted thousands of shares | 42,976 |
Balance sheet
CSVFiscal years (MAZE's year ends in late December)
| In thousands of dollars | Dec 31, 2025 |
|---|---|
| Cash and cash equivalents | 189,247 |
| Marketable securities | 152,670 |
| Marketable securities, non-current | 18,114 |
| Prepaid and other current assets | 7,800 |
| Total current assets | 349,717 |
| Property and equipment, net | 5,044 |
| Right-of-use asset | 20,116 |
| Total assets | 397,127 |
| Accounts payable | 1,794 |
| Total current liabilities | 22,556 |
| Lease liability, non-current | 18,511 |
| Total liabilities | 42,161 |
| Accumulated deficit | (489,547) |
| Total stockholders' equity | 354,966 |
| Total liabilities and equity | 397,127 |
| Common shares outstanding (cover page) thousands of shares | 49,336 |
Cash flows
CSVFiscal years (MAZE's year ends in late December)
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Maze Therapeutics | 202,643 | 0* | (15,053)* | 55.5M | 32.9 quarters | 10-QJun 30, 2026 |
| Theravance Biopharma | 219,766 | 20,731 | (6,965)* | 51.9M | 55.7 quarters | 10-QJun 30, 2026 |
| Zevra Therapeutics | 122,148 | 37,756 | 10,047* | 59.5M | — | 10-QSep 30, 2026 |
| aTYR PHARMA | 13,140 | 0 | (9,511)* | 2.5M | 4.6 quarters | 10-QSep 30, 2026 |
| Arvinas | 88,000 | 500 | (10,400)* | 65.5M | 13.0 quarters | 10-QSep 30, 2026 |
| CytoDyn | 16,359 | not reported | (7,726) | 1.5B | 2.1 quarters | 10-QAug 31, 2026 |
| Arbutus Biopharma | 19,171 | 1,014 | (6,018)* | 197.8M | 15.4 quarters | 10-QJun 30, 2026 |
| Cryoport | 279,179 | 50,220 | 5,214* | 50.7M | — | 10-QSep 30, 2026 |
| Capricor Therapeutics | 20,935 | not reported | (31,485)* | 58.1M | 7.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.